ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ZEG - GB0009895292 - Common Stock
157.85 EUR
+0.2 (+0.13%)
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. ZEG has an excellent profitability rating, but there are concerns on its financial health. ZEG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
ZEG had positive earnings in each of the past 5 years.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
ZEG has a better Return On Assets (8.21%) than 67.31% of its industry peers.
ZEG has a better Return On Equity (20.48%) than 71.15% of its industry peers.
ZEG has a better Return On Invested Capital (14.42%) than 73.08% of its industry peers.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 13.72%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (16.17%) is better than 67.31% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
ZEG has a better Operating Margin (24.34%) than 63.46% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
ZEG's Gross Margin of 81.90% is amongst the best of the industry. ZEG outperforms 84.62% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
ZEG has about the same amout of shares outstanding than it did 1 year ago.
ZEG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
ZEG has an Altman-Z score of 6.03. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ZEG (6.03) is better than 82.69% of its industry peers.
ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
ZEG has a Debt to FCF ratio (3.41) which is in line with its industry peers.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, ZEG is in line with its industry, outperforming 48.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 6.03 |
ROIC/WACC1.6
WACC9.01%
2.3 Liquidity
ZEG has a Current Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.88, ZEG is not doing good in the industry: 80.77% of the companies in the same industry are doing better.
ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a worse Quick ratio (0.69) than 76.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.32, which indicates a rather expensive current valuation of ZEG.
ZEG's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of ZEG to the average of the S&P500 Index (26.51), we can say ZEG is valued slightly cheaper.
ZEG is valuated rather expensively with a Price/Forward Earnings ratio of 17.85.
ZEG's Price/Forward Earnings is on the same level as the industry average.
ZEG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.32 | ||
| Fwd PE | 17.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than 69.23% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 65.38% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 60.15 | ||
| EV/EBITDA | 28.88 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)1.09
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.63%, ZEG has a reasonable but not impressive dividend return.
ZEG's Dividend Yield is a higher than the industry average which is at 2.20.
Compared to an average S&P500 Dividend Yield of 2.00, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
FRA:ZEG (12/30/2025, 7:00:00 PM)
157.85
+0.2 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap489.42B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target166.38 (5.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend2.53
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)3.89%
PT rev (3m)6.22%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.32 | ||
| Fwd PE | 17.85 | ||
| P/S | 9.9 | ||
| P/FCF | 60.15 | ||
| P/OCF | 38.01 | ||
| P/B | 12.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.88 |
EPS(TTM)7.77
EY4.92%
EPS(NY)8.85
Fwd EY5.6%
FCF(TTM)2.62
FCFY1.66%
OCF(TTM)4.15
OCFY2.63%
SpS15.95
BVpS12.59
TBVpS-3.71
PEG (NY)1.7
PEG (5Y)1.09
Graham Number46.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 6.03 |
F-Score7
WACC9.01%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status of ASTRAZENECA PLC (ZEG.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
What is the valuation of ASTRAZENECA PLC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.32 and the Price/Book (PB) ratio is 12.54.
Can you provide the expected EPS growth for ZEG stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 11.95% in the next year.